What we found on the web about Denosumab
Denosumab - Wikipedia, the free encyclopedia
Denosumab (formerly known as AMG 162, proposed trade name Prolia is a fully-human monoclonal antibody which is being studied in the treatment of osteoporosis, treatment-induced ...
Juncos, Puerto Rico - Wikipedia, the free encyclopedia
Amgen is also adding manufacturing capacity in Juncos to produce Denosumab. In addition to Amgen there is a Medtronic and Becton Dickinson Caribe Ltd. in Juncos.
Denosumab for osteoporosis
: New phase 2 results show the fully human monoclonal antibody may be an effective treatment for osteoporosis. While concerns remain over the long-term effects of disrupting this ...
Amgen says denosumab similar to Zometa in study
THOUSAND OAKS, Calif. - Biotechnology company Amgen Inc. said Monday its drug denosumab met the goals of a late-stage study in treating patients with cancer that has spread to ...
Denosumab—Great Expectations for Amgen and Osteoporosis Market
Patricia F. Dimond, Ph.D. An FDA advisory committee will convene on August 13 to discuss, what is considered by some, Amgen’s fate as a biotech giant. The panel will vote on ...
Denosumab Adherence Preference Satisfaction Study - Full Text View ...
The primary objective is to evaluate the adherence of subjects to SC 60 mg denosumab Q6M treatment compared to oral 70 mg alendronate QW treatment at the end of treatment period 1 ...
Denosumab | Osteoporosis | Osteopenia
Denosumab | Osteoporosis drugs ... Denosumab Osteoporosis and improved bone density. Denosumab, a new Osteoporosis drug was submitted to the FDA for its approval in February 2009.
Denosumab, Amgen D-mab - FierceBiotech
Drug: DenosumabCompany: Amgen Scoop: Denosumab is a fully-human monoclonal antibody which Amgen is studying for a number of indications, including osteoporosis, treatment-induced ...
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase ...
Originally published as JCO Early Release 10.1200/JCO.2008.16.3832 on August 25 2008. Journal of Clinical Oncology, Vol 26, No 30 (October 20), 2008: pp. 4875-4882
Denosumab New Drug Application
Denosumab is a new drug in development for the treatment of postmenopausal osteoporosis and in patients undergoing hormone ablation for either prostate or breast cancer.
Denosumab fortifies bone in breast cancer patients | Health | Reuters ...
LOS ANGELES (Reuters) - The osteoporosis drug denosumab increased bone strength in women receiving hormone therapy for breast cancer, drug maker Amgen Inc said Friday. The results ...
Amgen - In the News - Pipeline in the News
Amgen’s Statement in Response to Sheffield Telegraph Story on Denosumab. Below is Amgen’s statement in response to a Sheffield Telegraph story about a coroner’s inquest held ...
Denosumab in Osteoporosis and Oncology (September)...[Ann Pharmacother ...
PubMed is a service of the U.S. National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to ...
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Denosumab

Denosumab (formerly known as AMG 162, proposed trade name Prolia is a fully-human monoclonal antibody which is being studied in the treatment of osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, multiple myeloma and giant cell tumor of bone.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Denosumab
Amgen osteoporosis drug denosumab wins a vote of confidence from FDA panel
Los Angeles Times
The experimental drug benefits patients being treated for osteoporosis, advisory panel says. But it does not recommend it for preventive use. The FDA is due to decide in October. Biotech leader Amgen Inc. cleared a major hurdle in its push ...
Amgen’s Bone Drug May Pose Safety Risks, FDA Says (Update3)
Bloomberg
Aug. 11 (Bloomberg) -- A “slightly increased” risk of infections and tumors with Amgen Inc. ’s lead experimental product, the bone-strengthening drug denosumab, must be weighed against the benefits of fewer fractures by U.S. advisers ...
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
New England Journal of Medicine
Background Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-B ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, ...
RPT-PREVIEW-US review of Amgen bone drug to focus on safety
Reuters
LOS ANGELES, Aug 9 (Reuters) - Thursday's U.S. Food and Drug Administration advisory panel review of denosumab, Amgen Inc's ( AMGN.O ) experimental osteoporosis drug, will likely center on safety, particularly the risk of serious infections...
Denosumab to Affect Multiple Layers of Immune System
Pravda Ru
Two studies suggest a new osteoporosis drug lowers the risk of bone fractures as well as or better than current medicines. The genetically engineered drug, called denosumab, was tested in older women and men with prostate cancer . It's made...
Denosumab helps reduce fractures, increases bone density
SAWF News Connect
Denosumab, a human monoclonal antibody, reduces the risk of new vertebral fractures by 68 percent in postmenopausal women with osteoporosis. It also reduces the risk of new hip fractures by 40 percent, and nonvertebral fractures by 20 perce...
Studies: New osteoporosis drug cuts fracture risk
Newsday
Amgen Inc . will stress that only two shots of its genetically engineered denosumab, which could be approved for sale this fall, are needed each year. That's important because many patients stop taking other drugs due to side effects or fre...